ArticleCancer discovery2024

Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.

William K Kelly et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.